Bispecific Antibodies in Aggressive B-Cell Lymphoma: Real-World Insights and Future Directions

episode

Blood Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Best of the Bears: Week 2 vs. Vikings 41 min · 20 Sep 2026 · Rahimi & Grote Show

Pat's Sunday Paper Review 20th September 17 min · 20 Sep 2026 · The Pat Kenny Show

NPR News: 09-20-2026 5AM EDT 4 min · 20 Sep 2026 · NPR News Now

5AM ET 09/20/2026 Newscast 3 min · 20 Sep 2026 · Fox News Hourly Update

667: Why this doctor stopped fearing sugar, ice cream, & alcohol | Keshav Grover, D.O, M.S. 46 min · 20 Sep 2026 · The mindbodygreen Podcast

Begin Again Moments: Growing Up With A Narcissistic Parent 12 min · 20 Sep 2026 · Begin Again with Davina McCall

Report any issue

Source

Recorded06 Nov 2025

Publisherfeeds.transistor.fm ↗

Handlerec:11741874

Show notes

In this week's episode, Blood editor Dr. Laura Michaelis interviews author Dr. Taylor Brooks on his latest paper published in volume 146 issue 18 of Blood Journal. The conversation discusses outcomes of bispecific antibodies (epcoritamab or glofitamab) in treating aggressive B-cell lymphoma in a study with 245 patients. Findings show a tentative way forward in treatment for patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL).Featured Article:Real-world outcomes of patients with aggressive B-cell lymphoma treated with epcoritamab or glofitamab

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in